Purcell & Lefkowitz LLP is investigating AN2 Therapeutics, Inc. on behalf of its shareholders to determine if the company's directors breached their fiduciary duties related to recent corporate actions. The investigation aims to protect shareholder rights and explore potential legal options. Shareholders interested in more information or legal advice can contact the firm directly. This inquiry highlights concerns about corporate governance at AN2 Therapeutics and may lead to legal proceedings if breaches are confirmed.
AN2 Therapeutics shareholder investigation news arrives as 64 of 128 Health-sector US stocks on Pluang rose today. For readers following health stocks, here is Pluang's market snapshot as of Oct 12, 2026 18:51 WIB: Biogen Inc (BIIB) gained 3.39% to USD 233.37 with a typical hold time of 111 days, Enveric Biosciences Inc (ENVB) fell 3.45% to USD 1.40 with a 14-day hold, and Roivant Sciences Ltd (ROIV) dropped 2.09% to USD 34.70 with a 3-day hold.
Alignment Health Plan introduced Central Health Harmony, a new Medicare Advantage plan starting January 1, 2027, targeting Asian American seniors in Los Angeles and Orange counties. The plan offers access to over 600 physicians who speak Chinese, Kor...
NVIDIA and Cisco have introduced Ultra-Dense Small Form Factor Pluggable (USFP), a new optical module supporting 400Gb/s per lane, enabling up to 12.8Tb/s capacity for AI data centers. This technology doubles bandwidth per lane and increases power ef...
Hasbro announced the fourth annual Women Innovators of Play Design Challenge, accepting submissions from October 15 to November 20, 2026. The program now includes year-round in-person networking events alongside the design competition, aiming to conn...
Micas Networks introduced three new 102.4 Tbps open Ethernet switch platforms based on Broadcom Tomahawk 6 technology, designed to enhance AI factory networks. The portfolio includes air-cooled 800G, liquid-cooled 1.6T, and co-packaged optics (CPO) s...
Ferrari N.V. has repurchased 43,000 of its common shares on Euronext Milan as part of the third tranche of its multi-year €3.5 billion share buyback program announced in 2025. The recent purchases, totaling nearly €14.8 million, are part of a broader...
